BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180303
DTEND;VALUE=DATE:20180406
DTSTAMP:20260729T133032
CREATED:20180303T193121Z
LAST-MODIFIED:20180303T193121Z
UID:19739-1520035200-1522972799@ces.b2sg.org
SUMMARY:Postdoc Fellow - Cancer Biology (Myeloma)
DESCRIPTION:Translational Development at Celgene is pleased to present a growth opportunity for outstanding post-doctoral fellows with a passion for hematology-oncology research and clinical development towards improved outcomes in myeloma patient healthcare. The multiple myeloma Translational Development team currently employs state of the art platforms and analytics to address the most important questions that will drive the current and next generation of therapeutic development for myeloma patients. \nThe successful candidate will become part of diverse team with a unified bench-to-bedside vision in precision healthcare and diagnostic approaches to biomarker utilization. The overarching goal of the successful candidate will be to provide\, through passionate research efforts\, clinically implementable information to better understand how patient characteristics\, malignancy biology and immune context features align to define patient outcomes from treatment with portfolio therapeutics and enable rationale combo design. This fellowship will work alongside top shelf scientists with deep knowledge of myeloma disease biology and further expertise including genomic definition of risk and outcomes\, immune characterization\, definition of response and tumoral evolution using single cell platforms and lab-based screens to better understand mechanistics of clinically-observed phenomenon. \nSkills/Knowledge Required: \n\nPhD in cancer biology\, genetics\, epigenetics\nStrong background in disease or mechanism based studies using modern experimental and computational methods is required.\nKnowledge of myeloma is desirable but not required.\nExperience in heme malignancy related areas\nWhile understanding of epigenetics and epigenetic experimental approaches are not essential\, it is highly desirable.\nPrior experience in molecular\, cellular\, functional and computational methods\nAbility to formulate experimental ideas\nDemonstrated writing and commutation skills\nAbility work in a collaborative team science environment
URL:https://ces.b2sg.org/event/celgene-3mar18/
LOCATION:Celgene\, 86 Morris Ave\, Summit\, NJ\, 07901\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2017/08/celgene-1-e1503843775806.png
END:VEVENT
END:VCALENDAR